Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Pan Afr Med J ; 39: 13, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34394804

RESUMEN

INTRODUCTION: von Willebrand Disease (vWD) is the most prevalent bleeding disorder. Women are more likely to manifest abnormal bleeding symptoms due to physiologic events and menorrhagia is the most common presenting symptom. METHODS: this case-control study included 168 women aged between 18 and 45. The cases had menorrhagia whilst the controls did not. Blood grouping, activated partial thromboplastin time and von Willebrand factor activity tests were performed on samples collected from consenting study participants. RESULTS: the mean age was 29.96 ± 7.37. Mean vWF activity of cases was 66.6% and of controls 97.8%. The mean activated Partial ThromboplastinTime (aPTT) of cases was 31.09s and of controls was 30.40s. There was no difference in the vWF activity between blood group O (86.3%) and non-blood group O (88.0%) participants. Eight women were diagnosed with von Willebrand disease, 6 cases and 2 controls. Higher odds of von Willebrand disease were seen in the cases (OR = 6.6). Epistaxis, von Willebrand and factor activity levels and family history of menorrhagia were associated with an increased risk for menorrhagia. CONCLUSION: von Willebrand factor activity levels were associated with menorrhagia while activated partial thromboplastin time was not. vWF activity levels did not depend on any specific blood group. The prevalence of von Willebrand disease was significantly higher in participants with menorrhagia and repeated epistaxis and family history of menorrhagia pointed to a higher risk of menorrhagia.


Asunto(s)
Hemorragia/etiología , Menorragia/etiología , Enfermedades de von Willebrand/diagnóstico , Factor de von Willebrand/metabolismo , Adolescente , Adulto , Biomarcadores/metabolismo , Estudios de Casos y Controles , Epistaxis/epidemiología , Femenino , Humanos , Persona de Mediana Edad , Tiempo de Tromboplastina Parcial , Prevalencia , Adulto Joven , Zambia , Enfermedades de von Willebrand/complicaciones
3.
Afr Health Sci ; 18(3): 496-502, 2018 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-30602980

RESUMEN

BACKGROUND: Human Parvovirus (B19V) is a small, single-stranded, non-enveloped DNA virus which is pathogenic to humans causing a wide array of clinical complications which include erythema infectiosum, aplastic crisis and hydrops foetalis. It is generally harmless in healthy individuals but may be life threatening in immunocompromised individuals such as patients with sickle cell disease, cancer, HIV and pregnant women. It has been shown to be transmissible by blood transfusion but donor screening for the virus is not yet mandatory in most sub-Saharan African countries including Zambia. MATERIALS AND METHODS: This was a cross-sectional study undertaken at the Kitwe Central Hospital, blood bank and Tropical Diseases Research Centre at Ndola Central Hospital. A total of 192 blood samples were screened for Ig M antibodies against parvovirus B19 by ELISA. OBJECTIVES: The general objective of the study was to determine the seroprevalence of parvovirus B19 infections among healthy blood donors at the Kitwe Central Hospital blood bank. Specific Objectives were to detect parvovirus B19 Ig M antibodies in donor blood using serology and to analyse the age and sex distribution of parvovirus among blood donors. RESULTS: The prevalence of parvovirus B19 Ig M in this study was 15.6%. The majority of the positive cases were in the age group 15-22 years (17.8%) but there was no statistical significance between occurrence of parvovirus and age ( p value=0.703). Prevalence in males was higher than in females that is 16.4% and 13.8%, respectively. The relationship between gender and parvovirus B19 occurrence was however not significant either (p value=0.516). CONCLUSION: This study showed a 15.6% prevalence rate of acute Parvovirus B19 infections in blood donors at the Kitwe Central Hospital, blood bank. Studies with larger sample sizes are needed to validate these results.


Asunto(s)
Donantes de Sangre , Transfusión Sanguínea , Inmunoglobulina M/sangre , Infecciones por Parvoviridae/epidemiología , Parvovirus B19 Humano/inmunología , Adulto , Anticuerpos Antivirales/sangre , Bancos de Sangre , Estudios Transversales , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Seroepidemiológicos , Zambia/epidemiología
4.
J Trop Pediatr ; 50(6): 377-8, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15537729

RESUMEN

The last successfully treated case of congenital trypanosomiasis in Zambia was in October 1978, with detailed analysis of immunoglobulins, illustrating the waning of blood and serum levels of IgA, IgG, and IgM during treatment, up to 99 days after treatment. Twenty-five years later, we report on a case of congenital trypanosomiasis. The disease is now rare and can be missed or dismissed as retroviral disease, particularly in adults. The main unusual symptoms were the prolonged intermittent convulsions in an otherwise well infant. Management of the disease is now more interdisciplinary, resources for laboratory support are fewer, lumbar puncture is more relevant, and antitrypanosomal drugs are more difficult to obtain. The mother died within one week of hospitalization and the infant initially responded to three doses of suramin and 3 weeks of melsopropol. Convulsions ceased during the second round of melsopropol. Unfortunately, the infant died of nosocomial infection.


Asunto(s)
Transmisión Vertical de Enfermedad Infecciosa , Complicaciones Parasitarias del Embarazo/diagnóstico , Tripanosomiasis/congénito , Tripanosomiasis/diagnóstico , Adulto , Países en Desarrollo , Progresión de la Enfermedad , Resultado Fatal , Femenino , Humanos , Lactante , Embarazo , Medición de Riesgo , Índice de Severidad de la Enfermedad , Tripanocidas/uso terapéutico , Tripanosomiasis/terapia , Zambia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA